Enhertu, a breast cancer drug from AstraZeneca and Daiichi Sankyo, is now FDA approved for treating patients whose tumors express low levels of the protein HER2. The decision makes the infused therapy the first targeted treatment for this new category of breast cancer patients.
During the annual meeting of the American Society of Clinical Oncology, AstraZeneca and Daiichi Sankyo reported pivotal clinical trial data showing that their partnered cancer drug Enhertu can treat a group of patients previously thought to be out of reach for a targeted therapy. The results suggest use of this FDA-approved drug could significantly expand to more breast cancer patients.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Gilead Sciences has more detail about breast cancer drug Trodelvy, a blockbuster hopeful it acquired two years ago. Additional data from a pivotal study were presented during the annual meeting of the American Society of Clinical Oncology and they still leave many questions unanswered.
Startup iSono Health said its FDA-cleared automated imaging system will make personalized whole breast imaging more accessible to women worldwide and could help improve breast cancer diagnosis.
Athelo Health’s software is a personal coach that supports women with breast and gynecological cancers. The startup was judged co-winner in the pharmatech category during the recent MedCity INVEST conference in Chicago.
Biotech startup Pheast Therapeutics is out of stealth taking a tack similar to that of cancer immunotherapy company Forty Seven, also a spinout from the Stanford University lab of Irving Weissman. While both companies get immune cells to eat tumors, Pheast’s technology has the potential to take the approach to a broader range of cancer types including those that have historically resisted immunotherapy.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Experimental Roche drug giredestrant failed to meet the main goal of a Phase 2 study in advanced breast cancer. The disappointing results allow competitors to gain ground in the field of companies developing oral selective estrogen receptor degraders (SERDs), drugs that block a receptor key to driving breast cancer growth.
There is a need for sophisticated and accurate forecasting software tools that incorporate precision cancer care. Technology and artificial intelligence, in particular, have the potential to improve clinical decision-making.
As health systems play catch up with backlogged – and potentially life-saving – screenings, it’s important they prioritize people at higher risk, to ensure they have access to the preventive care they need.
A review of 12 studies about AI systems used to screen patients for breast cancer found that they lacked evidence to prove that they would work well in a clinical setting. Researchers highlighted concerns about study quality, including the fact that all of the studies were retrospective and many of them had a high risk of bias.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Clinical trials are the safest and most trusted route for identifying new breast cancer treatments, and the more research that can be done, the closer we will be to eradicating breast cancer for good.
Arvinas’ early clinical data for its targeted protein degradation drug for breast cancer drew partnering interest from several companies. Pfizer beat them all with a deal that pays the biotech $1 billion to share in the development and commercialization of this therapy.
As an industry, we should be proud of all that we have accomplished in making precision medicine a reality, whether it has been through advances in screening, drug development, diagnostics, or delivery. However, our work has just begun.
The American Society of Clinical Oncology’ annual meeting featured news highlights from the Merck, Novartis, and other drug giants. Meanwhile, some small biotechs rode the coattails of their larger counterparts and others forged their own paths with promising early results for new cancer drug targets.
Athenex’s bid to offer an oral version of an intravenous chemotherapy has stalled after the FDA rejected the drug. Among the remedies proposed by the regulator is another Phase 3 study.